uman big 180 ie/ml injektionsvæske, opløsning
orifarm a/s - hepatitis b immunglobulin, humant - injektionsvæske, opløsning - 180 ie/ml
uplizna
horizon therapeutics ireland dac - inebilizumab - neuromyelitis optica - immunosuppressiva - uplizna is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (nmosd) who are anti-aquaporin 4 immunoglobulin g (aqp4-igg) seropositive (see section 5.
kinpeygo
stada arzneimittel ag - budesonide, micronised - glomerulonephritis, iga - antidiarrémidler, tarm antiinflammatorisk / antiinfective agenter - kinpeygo is indicated for the treatment of primary immunoglobulin a (iga) nephropathy (igan) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (upcr) ≥1. 5 g/gram.
xembify 200 mg/ml injektionsvæske, opløsning
instituto grifols s.a. - normalt immunoglobulin til intravenøs brug, humant - injektionsvæske, opløsning - 200 mg/ml
fabrazyme
sanofi b.v. - agalsidase beta - fabry disease - andre alimentary tract and metabolism produkter, - fabrazyme er indiceret til langsigtet enzymudskiftningsterapi hos patienter med en bekræftet diagnose af fabrys sygdom (a-galactosidase-a-mangel).
elfabrio
chiesi farmaceutici s.p.a - pegunigalsidase alfa - fabry disease - andre alimentary tract and metabolism produkter, - elfabrio is indicated for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of fabry disease (deficiency of alpha-galactosidase).
galafold
amicus therapeutics europe limited - migalastat hydrochloride - fabry disease - migalastat - galafold er indiceret til langvarig behandling af voksne og unge i alderen 16 år og ældre med en bekræftet diagnose af fabrys sygdom (a-galactosidase a-mangel) og som har en acceptabel mutation.
replagal
takeda pharmaceuticals international ag ireland branch - agalsidase alfa - fabry disease - andre alimentary tract and metabolism produkter, - replagal er indiceret til langsigtet enzymudskiftningsterapi hos patienter med en bekræftet diagnose af fabrys sygdom (a-galactosidase-a-mangel).
poteligeo
kyowa kirin holdings b.v. - mogamulizumab - sezary syndrome; mycosis fungoides - antineoplastiske midler - poteligeo er indiceret til behandling af voksne patienter med mycosis fungoides (mf) eller sézary syndrom (ss), der har modtaget mindst én tidligere systemisk terapi.
atectura breezhaler
novartis europharm limited - indacaterol acetate, mometasone furoate - astma - medicin for obstruktiv sygdomme, - atectura breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.